Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) Director Ken Takanashi acquired 22,053,581 shares of Satsuma Pharmaceuticals stock in a transaction dated Tuesday, June 6th. The shares were purchased at an average price of $0.91 per share, with a total value of $20,068,758.71. Following the acquisition, the director now owns 24,847,694 shares of the company’s stock, […]
Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) was the recipient of a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 130,100 shares, a decrease of 58.0% from the April 30th total of 310,100 shares. Approximately 0.5% of the shares of the stock are sold […]
HC Wainwright cut shares of Satsuma Pharmaceuticals (NASDAQ:STSA – Get Rating) from a buy rating to a neutral rating in a report released on Tuesday morning, The Fly reports. Separately, Mizuho reaffirmed a neutral rating and set a $2.00 target price on shares of Satsuma Pharmaceuticals in a research report on Thursday, March 30th. Four […]